Risk Stratification in Older Intensively Treated Patients With AML.
Jurjen VersluisMarlen MetznerAriel WangPatrycja GradowskaAbin ThomasNiels Asger JakobsenAlison KennedyRachel MooreEmma BoertjesChristian M VonkFrancois G KavelaarsMelissa RijkenAmanda GilkesClaire SchwabH Berna BeverlooMarkus Gabriel ManzOtto VisserCatharina H M J Van ElssenOkke de WeerdtLidwine W TickBart J BiemondMarie-Christiane VekemansSylvie D FreemanChristine J HarrisonJonathan Alistair CookMike DennisStephen KnapperIan ThomasCharles F CraddockGert J OssenkoppeleBob LöwenbergNigel H RussellPeter J M ValkParesh VyasPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The new AML60+ classification provides prognostic information for intensively treated patients 60 years and older with AML and HR-MDS and identifies patients who benefit from intensive chemotherapy and allo-HCT.
Keyphrases
- acute myeloid leukemia
- newly diagnosed
- end stage renal disease
- ejection fraction
- allogeneic hematopoietic stem cell transplantation
- physical activity
- community dwelling
- machine learning
- middle aged
- deep learning
- genome wide
- prognostic factors
- healthcare
- radiation therapy
- gene expression
- locally advanced
- cell proliferation
- health information
- acute lymphoblastic leukemia
- patient reported
- signaling pathway
- cell death